Acute HIV infection
Conditions
Interventions
Peg-IFN combined with ART group:Peg-IFN combined with ART regimen treatment.
ART group:either DTG or BIC-based ART regimen
Sponsors
Beijing Youan Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1.Meet the diagnostic criteria for acute HIV infection as defined in the Guidelines for Diagnosis and Treatment of HIV/AIDS in China (2024 Edition); 2.Aged between 18 and 60 years; 3.No prior anti-HIV therapy; 4.Capable of providing written informed consent and willing to voluntarily participate in this clinical study;
Exclusion criteria
Exclusion criteria: 1.Patients with co-infection of viral hepatitis; 2.Patients with a history of or current diagnosis of liver cirrhosis or hepatocellular carcinoma; 3. Pregnant or breastfeeding women, or those planning to conceive in the near future; 4. Patients with a history of severe cardiac diseases, including unstable or uncontrolled cardiac conditions within the past 6 months; 5. Patients with uncontrolled diabetes, hypertension, thyroid disorders, retinopathy, clinically significant ophthalmologic conditions, autoimmune diseases, epilepsy, or other similar conditions; 6.Laboratory findings meeting any of the following criteria: • Neutrophil count 10 × ULN, or total bilirubin > 34 µmol/L; 7. Patients with opportunistic infections associated with HIV; 8. Patients with malignant tumors or contraindications to interferon therapy (e.g., interferon allergy, severe pulmonary diseases); 9.Patients with a history of psychiatric disorders; 10. Patients with a history of alcoholism, substance abuse, or drug misuse; 11. Any other condition that, in the opinion of the investigator, deems the patient unsuitable for participation in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage decrease in HIV DNA after 48 weeks of treatment.; | — |
Secondary
| Measure | Time frame |
|---|---|
| Percentage decrease in HIV DNA after 12 weeks of treatment.;CD4+ T cell growth rates at 12 and 48 weeks of treatment;Cytokine levels;inhibition rate of HIV RNA;Adverse event rate; | — |
Countries
China
Contacts
Public ContactZhang Tong
Beijing Youan Hospital, Capital Medical University
Outcome results
None listed